Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.8.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
NET REVENUE      
Clinical Services $ 231,748 $ 222,015 $ 98,595
Pharma Services 26,863 22,068 1,207
Total Revenue 258,611 244,083 99,802
Cost of revenue 138,295 133,704 56,046
GROSS MARGIN 120,316 110,379 43,756
Operating expenses:      
General and administrative 88,755 75,782 33,631
Research and development 3,636 4,649 4,198
Sales and marketing 24,543 23,910 11,562
Loss on sale of Path Logic 1,058    
Impairment charges 253 3,464  
Total operating expenses 117,992 107,805 49,391
INCOME (LOSS) FROM OPERATIONS 2,324 2,574 (5,635)
Interest expense and debt termination fees, net 5,540 9,998 854
Other expense (income) 265   (2,000)
(Loss) before taxes (3,481) (7,424) (4,489)
Income tax benefit 2,635 1,701 1,954
NET(LOSS) (846) (5,723) (2,535)
Deemed dividends on preferred stock 3,645 18,011 40
Amortization of preferred stock beneficial conversion feature 6,902 6,663 82
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (11,393) $ (30,397) $ (2,657)
NET (LOSS) PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS      
Basic $ (0.14) $ (0.39) $ (0.04)
Diluted $ (0.14) $ (0.39) $ (0.04)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:      
Basic 79,426 77,542 60,526
Diluted 79,426 77,542 60,526